82 related articles for article (PubMed ID: 21428246)
21. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
22. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients.
Wu CJ; Lin HC; Lee KF; Chuang CK; Chen YC; Chen HH
Nephrology (Carlton); 2010 Feb; 15(1):42-7. PubMed ID: 20377770
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations.
Span K; Pieters EHE; Brinks V; Hennink WE; Schellekens H
J Pharmacol Toxicol Methods; 2018; 91():7-17. PubMed ID: 29278742
[TBL] [Abstract][Full Text] [Related]
24. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Nysaeter G; Johansen J; Ostborg J; Berstad A; Berge RK; Hausken T
Scand J Gastroenterol; 2005 Sep; 40(9):1058-65. PubMed ID: 16165718
[TBL] [Abstract][Full Text] [Related]
25. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
Di Francesco T; Philipp E; Borchard G
Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
[TBL] [Abstract][Full Text] [Related]
26. Iron sucrose induced morphological and functional changes in the rat kidney.
Breborowicz A; Polubinska A; Górna K; Breborowicz M; Oreopoulos DG
Transl Res; 2006 Nov; 148(5):257-62. PubMed ID: 17145571
[TBL] [Abstract][Full Text] [Related]
27. Bioavailability of trivalent iron in oral iron preparations. Therapeutic efficacy and iron absorption from simple ferric compounds and high- or low-molecular weight ferric hydroxide-carbohydrate complexes.
Heinrich HC
Arzneimittelforschung; 1975 Mar; 25(3):420-6. PubMed ID: 1174047
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers.
Danielson BG; Salmonson T; Derendorf H; Geisser P
Arzneimittelforschung; 1996 Jun; 46(6):615-21. PubMed ID: 8767353
[TBL] [Abstract][Full Text] [Related]
30. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
31. Use of iron sucrose in dialysis patients sensitive to iron dextran.
Haddad A; Abbadi R; Marji A
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):208-11. PubMed ID: 19237805
[TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.
Shah RB; Yang Y; Khan MA; Raw A; Yu LX; Faustino PJ
Int J Pharm; 2014 Apr; 464(1-2):46-52. PubMed ID: 24440404
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
34. Physicochemical characteristics of Sonazoid, a new contrast agent for ultrasound imaging.
Sontum PC
Ultrasound Med Biol; 2008 May; 34(5):824-33. PubMed ID: 18255220
[TBL] [Abstract][Full Text] [Related]
35. Milk iron content in breast-feeding mothers after administration of intravenous iron sucrose complex.
Breymann C; von Seefried B; Stahel M; Geisser P; Canclini C
J Perinat Med; 2007; 35(2):115-8. PubMed ID: 17302514
[TBL] [Abstract][Full Text] [Related]
36. Peritoneal effects of intravenous iron sucrose administration in rats.
Breborowicz A; Polubinska A; Breborowicz M; Simon M; Wanic-Kossowska M; Oreopoulos DG
Transl Res; 2007 Jun; 149(6):304-9. PubMed ID: 17543848
[TBL] [Abstract][Full Text] [Related]
37. [Is there an indication for intravenous iron replacement in, for example, by autologous blood donation-induced iron deficiency and is there a theoretically possible indication for intravenous administration for the not approved Ferrum Hausmann preparation?].
Kruse HJ; Creutzig A
Internist (Berl); 1996 Oct; 37(10):1059. PubMed ID: 9019452
[No Abstract] [Full Text] [Related]
38. Bioavailability of iron from oral ferric polymaltose in humans.
Nielsen P; Gabbe EE; Fischer R; Heinrich HC
Arzneimittelforschung; 1994 Jun; 44(6):743-8. PubMed ID: 8053973
[TBL] [Abstract][Full Text] [Related]
39. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
40. Intravenous iron therapy: well-tolerated, yet not harmless.
Sengölge G; Hörl WH; Sunder-Plassmann G
Eur J Clin Invest; 2005 Dec; 35 Suppl 3():46-51. PubMed ID: 16281958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
